<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02698124</url>
  </required_header>
  <id_info>
    <org_study_id>AMLMDSWP-201601</org_study_id>
    <nct_id>NCT02698124</nct_id>
  </id_info>
  <brief_title>Decitabine for Chemotherapy Unfit Korean AML Patients in Real Practice</brief_title>
  <acronym>PURPLE-D</acronym>
  <official_title>Prospective Observation of the indUction Regimen for Acute Non-Promyelocytic Myeloid Leukemia in Elderly; Decitabine for Chemotherapy Unfit Korean Acute Myeloid Leukemia (AML) Patients in Real Practice</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ulsan University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Korean Society of Hematology, AML/MDS Working Party</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Ulsan University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective multicenter, open-lab el, observational, single arm study of decitabine. Subjects
      will be elderly patients with newly diagnosed, treatment-naïve AML who are unfit to receive
      and not candidate for intensive induction chemotherapy (iIC)
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>March 2016</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">August 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Ecologic or Community</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The rate of complete remission</measure>
    <time_frame>after 4 cycles of decitabine treatment (about 4 months)</time_frame>
    <description>The rate of complete remission and complete remission with incomplete platelet recovery (CRp) will be measured by 4 cycles of decitabine treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The rate of composite CR</measure>
    <time_frame>after 4 cycles of decitabine treatment (about 4 months)</time_frame>
    <description>CR+CRp+ CR with incomplete blood count recovery (CRi)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical benefit rate</measure>
    <time_frame>after 4 cycles of decitabine treatment (about 4 months)</time_frame>
    <description>cCR(CR+CRp+CRi)+ partial remission (PR)+ stable disease (SD)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of quality of life scale using EQ-5D-3L</measure>
    <time_frame>after 4 cycles of decitabine treatment (about 4 months)</time_frame>
    <description>Quality of life measurement by EQ-5D will be compared between pre- and post-decitabine therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of quality of life scale using EORTC QLQ-C30</measure>
    <time_frame>after 4 cycles of decitabine treatment (about 4 months)</time_frame>
    <description>Quality of life measurement by EORTC QLQ-C30 will be compared between pre- and post-decitabine therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with treatment-related adverse events as assessed by CTCAE v4.03</measure>
    <time_frame>until 4 cycles of decitabine treatment (about 4 months)</time_frame>
    <description>CTCAE version 4.03</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">136</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <condition>Elderly</condition>
  <condition>Intensive Chemotherapy Unfit</condition>
  <arm_group>
    <arm_group_label>Decitabine</arm_group_label>
    <description>Decitabine 20mg/m2 will be given IV daily on Days 1-5 in 28-day cycles. Treatment should be given for at least 4 cycles in the absence of unacceptable toxicity or disease progression requiring alternative therapy.
Beyond 4 cycles, treatment should continue as long as the subject continues to benefit based on investigator's judgment of no definitive progression.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Decitabine</intervention_name>
    <arm_group_label>Decitabine</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      miRNA, TET, whole genome sequencing
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        elderly patients with previously untreated AML who are ufit to receive and not considered
        candidates for iIC at the time of enrollment
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Newly diagnosed and therapy-naïve AML (bone marrow or peripheral blood blast counts
             ≥20%)

          2. 65 years of age or older

          3. Taking informed consent with signature and date

          4. Not eligible for iIC based on either:

        i) ≥75 years of age ii) comorbidity iii) secondary AML iv) poor performance (ECOG ≥2) v)
        Poor-risk by NCCN Guideline version 1.2015 vi) subject's choice (refusal for iIC)
        investigator's judgement incompatible with iIC

        Exclusion Criteria:

          1. Candidate for iIC at the time of enrollment

          2. Promyelocytic leukemia, or AML with t(15;17) or PML/RARα rearrangement

          3. AML with t(9;22) or BCR/ABL rearrangement

          4. Leukemia central nervous system involvement

          5. Extramedullary myeloid sarcoma without bone marrow involvement

          6. Prior treatment with decitabine or azacitidine of any cause

          7. Any leukemia-specific therapy, except for hydroxyurea for reducing leukemic cells
             prior decitabine

          8. Second malignancy currently requiring active therapy except breast or prostate cancer
             stable on or responding to endocrine therapy, or curatively resected non-melanoma skin
             cancer or intraepithelial cancer

          9. Premenopausal woman

         10. Severe active infection

         11. Uncontrolled bleeding Hypersensitivity to decitabine
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Ulsan University Hospital</name>
      <address>
        <city>Ulsan</city>
        <zip>682714</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hawk Kim, M.D., Ph.D.</last_name>
      <phone>+82-52-250-8892</phone>
      <email>kimhawkmd@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Hawk Kim, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jae-Cheol Cho, M.D., Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yunsuk Choi, M.D., Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <results_reference>
    <citation>Kantarjian HM, Thomas XG, Dmoszynska A, Wierzbowska A, Mazur G, Mayer J, Gau JP, Chou WC, Buckstein R, Cermak J, Kuo CY, Oriol A, Ravandi F, Faderl S, Delaunay J, Lysák D, Minden M, Arthur C. Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. J Clin Oncol. 2012 Jul 20;30(21):2670-7. doi: 10.1200/JCO.2011.38.9429. Epub 2012 Jun 11.</citation>
    <PMID>22689805</PMID>
  </results_reference>
  <results_reference>
    <citation>Blum W, Garzon R, Klisovic RB, Schwind S, Walker A, Geyer S, Liu S, Havelange V, Becker H, Schaaf L, Mickle J, Devine H, Kefauver C, Devine SM, Chan KK, Heerema NA, Bloomfield CD, Grever MR, Byrd JC, Villalona-Calero M, Croce CM, Marcucci G. Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine. Proc Natl Acad Sci U S A. 2010 Apr 20;107(16):7473-8. doi: 10.1073/pnas.1002650107. Epub 2010 Apr 5.</citation>
    <PMID>20368434</PMID>
  </results_reference>
  <results_reference>
    <citation>Mims A, Walker AR, Huang X, Sun J, Wang H, Santhanam R, Dorrance AM, Walker C, Hoellerbauer P, Tarighat SS, Chan KK, Klisovic RB, Perrotti D, Caligiuri MA, Byrd JC, Chen CS, James Lee L, Jacob S, Mrózek K, Bloomfield CD, Blum W, Garzon R, Schwind S, Marcucci G. Increased anti-leukemic activity of decitabine via AR-42-induced upregulation of miR-29b: a novel epigenetic-targeting approach in acute myeloid leukemia. Leukemia. 2013 Apr;27(4):871-8. doi: 10.1038/leu.2012.342. Epub 2012 Nov 26.</citation>
    <PMID>23178755</PMID>
  </results_reference>
  <results_reference>
    <citation>Suzuki H, Maruyama R, Yamamoto E, Kai M. DNA methylation and microRNA dysregulation in cancer. Mol Oncol. 2012 Dec;6(6):567-78. doi: 10.1016/j.molonc.2012.07.007. Epub 2012 Aug 10. Review.</citation>
    <PMID>22902148</PMID>
  </results_reference>
  <results_reference>
    <citation>Kim Y, Cheong JW, Kim YK, Eom JI, Jeung HK, Kim SJ, Hwang D, Kim JS, Kim HJ, Min YH. Serum microRNA-21 as a potential biomarker for response to hypomethylating agents in myelodysplastic syndromes. PLoS One. 2014 Feb 4;9(2):e86933. doi: 10.1371/journal.pone.0086933. eCollection 2014.</citation>
    <PMID>24503739</PMID>
  </results_reference>
  <results_reference>
    <citation>Castoro RJ, Dekmezian M, Saraf AJ, Watanabe Y, Chung W, Adhab SE, et al. MicroRNA 124 and Its Role in Response to Epigenetic Therapy in Patients with Acute Mylogenous Leukemia and Myelodysplastic Syndrome. American Society of Hematology 2008; Abstract No. 598</citation>
  </results_reference>
  <results_reference>
    <citation>Cheson BD, Bennett JM, Kopecky KJ, Büchner T, Willman CL, Estey EH, Schiffer CA, Doehner H, Tallman MS, Lister TA, Lo-Coco F, Willemze R, Biondi A, Hiddemann W, Larson RA, Löwenberg B, Sanz MA, Head DR, Ohno R, Bloomfield CD; International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol. 2003 Dec 15;21(24):4642-9. Erratum in: J Clin Oncol. 2004 Feb 1;22(3):576. LoCocco, Francesco [corrected to Lo-Coco, Francesco].</citation>
    <PMID>14673054</PMID>
  </results_reference>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 19, 2016</study_first_submitted>
  <study_first_submitted_qc>February 28, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 3, 2016</study_first_posted>
  <last_update_submitted>March 4, 2016</last_update_submitted>
  <last_update_submitted_qc>March 4, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 7, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ulsan University Hospital</investigator_affiliation>
    <investigator_full_name>Hawk Kim</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Decitabine</mesh_term>
    <mesh_term>Azacitidine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

